Related Experiment Video
Updated: Apr 27, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.4K
Plasma proteins predict conversion to dementia from prodromal disease.
Abdul Hye1, Joanna Riddoch-Contreras1, Alison L Baird1
1Institute of Psychiatry, Department of Old Age Psychiatry, King's College London, London, UK.
Summary
Ten plasma proteins show strong links to Alzheimer's disease (AD) progression. These biomarkers can aid in selecting patients for clinical trials and managing early memory complaints.
Area of Science:
- Biomarker discovery and validation
- Neurodegenerative disease research
- Alzheimer's disease (AD) diagnostics
Background:
- Previous research identified potential plasma biomarkers for AD.
- This study aimed to validate these biomarkers using neuroimaging for disease severity.
- The prognostic value for predicting dementia conversion was also assessed.
Purpose of the Study:
- To validate plasma biomarkers for Alzheimer's disease (AD).
- To assess the prognostic value of these biomarkers in predicting dementia.
- To utilize neuroimaging measures as a surrogate for disease severity.
Main Methods:
- Utilized three multicenter cohorts: cognitively healthy elderly, mild cognitive impairment (MCI), and AD patients.
- Employed standardized clinical assessments and structural neuroimaging.
- Quantified 26 candidate proteins in 1148 subjects using multiplex (xMAP) assays.
Main Results:
- Sixteen proteins demonstrated correlation with disease severity and cognitive decline.
- A panel of 10 proteins in the MCI group accurately predicted progression to AD (87% accuracy).
- This panel showed high sensitivity (85%) and specificity (88%) for predicting AD conversion.
Conclusions:
- Identified 10 plasma proteins significantly associated with AD severity and progression.
- These protein markers show potential for improving patient selection in clinical trials.
- The markers may assist in evaluating individuals with subjective memory complaints and predisease symptoms.
Keywords:
Alzheimer's diseaseBiomarkerMild cognitive impairmentPathologyPlasmaPrediction and magnetic resonance imagingMore Related Videos
Related Concept Videos
01:22Dementia l: Introduction
29
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
29
01:29Alzheimer Disease l: Introduction
19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
01:23Alzheimer Disease ll: Pathophysiology
27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:30Dementia
685
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
685
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K